Q3 2022 Earnings Forecast for Teva Pharmaceutical Industries Limited (NYSE:TEVA) Issued By Zacks Research

Teva Pharmaceutical Industries Limited (NYSE:TEVAGet Rating) – Stock analysts at Zacks Research dropped their Q3 2022 earnings estimates for shares of Teva Pharmaceutical Industries in a research note issued on Tuesday, September 20th. Zacks Research analyst K. Shah now anticipates that the company will earn $0.56 per share for the quarter, down from their prior forecast of $0.59. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.45 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries’ Q4 2022 earnings at $0.64 EPS, FY2022 earnings at $2.39 EPS, Q2 2023 earnings at $0.57 EPS and FY2024 earnings at $2.43 EPS.

TEVA has been the topic of a number of other reports. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Friday, June 17th. UBS Group initiated coverage on shares of Teva Pharmaceutical Industries in a research note on Monday, June 13th. They set a “neutral” rating and a $10.00 price objective on the stock. The Goldman Sachs Group increased their price objective on shares of Teva Pharmaceutical Industries from $9.00 to $10.00 and gave the company a “neutral” rating in a research note on Tuesday, August 2nd. Finally, Bank of America upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and increased their price objective for the company from $10.00 to $13.00 in a research note on Friday, August 5th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $10.67.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA stock opened at $8.06 on Thursday. The company has a debt-to-equity ratio of 2.07, a current ratio of 1.11 and a quick ratio of 0.74. The company has a market capitalization of $8.95 billion, a P/E ratio of -8.48, a P/E/G ratio of 3.27 and a beta of 1.27. The company’s 50-day simple moving average is $9.23 and its two-hundred day simple moving average is $8.72. Teva Pharmaceutical Industries has a one year low of $6.78 and a one year high of $11.34.

Teva Pharmaceutical Industries (NYSE:TEVAGet Rating) last issued its earnings results on Tuesday, July 26th. The company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.55 by $0.09. The business had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.82 billion. Teva Pharmaceutical Industries had a negative net margin of 6.83% and a positive return on equity of 25.68%.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Capital Research Global Investors raised its holdings in shares of Teva Pharmaceutical Industries by 11.3% during the fourth quarter. Capital Research Global Investors now owns 132,350,750 shares of the company’s stock worth $1,060,109,000 after purchasing an additional 13,474,099 shares during the last quarter. BlackRock Inc. increased its holdings in Teva Pharmaceutical Industries by 3.7% in the first quarter. BlackRock Inc. now owns 41,648,716 shares of the company’s stock valued at $391,081,000 after buying an additional 1,494,814 shares in the last quarter. Menora Mivtachim Holdings LTD. increased its holdings in Teva Pharmaceutical Industries by 1.3% in the first quarter. Menora Mivtachim Holdings LTD. now owns 23,310,610 shares of the company’s stock valued at $218,887,000 after buying an additional 308,328 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd increased its holdings in Teva Pharmaceutical Industries by 8.1% in the second quarter. Clal Insurance Enterprises Holdings Ltd now owns 18,962,766 shares of the company’s stock valued at $138,282,000 after buying an additional 1,424,200 shares in the last quarter. Finally, Phoenix Holdings Ltd. increased its holdings in Teva Pharmaceutical Industries by 10.0% in the first quarter. Phoenix Holdings Ltd. now owns 16,699,401 shares of the company’s stock valued at $156,809,000 after buying an additional 1,513,100 shares in the last quarter. Hedge funds and other institutional investors own 46.22% of the company’s stock.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, VP David Matthew Stark sold 58,163 shares of the firm’s stock in a transaction that occurred on Thursday, July 28th. The shares were sold at an average price of $9.04, for a total value of $525,793.52. Following the completion of the sale, the vice president now directly owns 2,974 shares in the company, valued at $26,884.96. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Teva Pharmaceutical Industries news, VP David Matthew Stark sold 58,163 shares of the firm’s stock in a transaction on Thursday, July 28th. The shares were sold at an average price of $9.04, for a total value of $525,793.52. Following the completion of the transaction, the vice president now owns 2,974 shares of the company’s stock, valued at $26,884.96. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO Eliyahu Sharon Kalif sold 55,500 shares of the firm’s stock in a transaction on Monday, August 22nd. The stock was sold at an average price of $10.07, for a total transaction of $558,885.00. Following the completion of the transaction, the chief financial officer now directly owns 9,376 shares of the company’s stock, valued at approximately $94,416.32. The disclosure for this sale can be found here. 0.82% of the stock is owned by insiders.

Teva Pharmaceutical Industries Company Profile

(Get Rating)

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams.

Read More

Earnings History and Estimates for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.